Kesimpta begins to work within a week of starting treatment, as it starts to lower B-cell levels in the body. Clinical studies have shown that significant reductions in MS relapses and disease progression can be observed as early as three months into treatment. However, individual responses may vary, and ongoing monitoring by healthcare providers is essential to evaluate the treatment’s effectiveness.